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ABSTRACT 
O2 delivery is dependent upon the ability of erythrocytes (diameter of ~8µm) to deform and to 
pass through the smaller microvasculature (~3µm).  Reduced erythrocyte deformability in 
hypoxia could ultimately compromise O2 delivery to the microvasculature of skeletal muscles 
during exercise, thus impairing performance.  Chronic supplementation with omega-3 fatty acids 
(PUFAs) has been shown to increase erythrocyte deformability, which may improve oxygenation 
and endurance exercise performance in acute hypoxia.  PURPOSE: To determine if chronic ω-3 
PUFA supplementation improves erythrocyte deformability, V̇O2, and cycling time to exhaustion 
during acute hypoxic exercise.  METHODS: Thirteen young, healthy, endurance-trained subjects 
were divided into PUFA (V̇O2max=60.2 ± 4.5 mL.kg-1.min-1, n=6) and placebo (66.2 ± 4.1 mL.kg-
1.min-1, n=7) groups.  Subjects completed 6 weeks of supplementation with either ω-3 PUFAs 
(PUFA group; 3g EPA, 2g DHA/day) or placebo (placebo group; safflower oil).  Subjects 
performed identical experimental sessions in acute normobaric hypoxia (FIO2=15%) pre- and 
post-supplementation that consisted of 3 min cycling  / 10 min rest at 25% and 50% of normoxic 
peak power, as well as cycling to exhaustion at 75% of normoxic peak power.  Erythrocyte 
elongation index (EI) via ektacytometry, V̇O2, and time to exhaustion were recorded for each 
trial.  RESULTS: EI at 20 Pa of shear stress was significantly greater (e.g. higher deformability) 
within the PUFA group post-supplementation (pre: 0.574 ± 0.004; post: 0.580 ± 0.003; p<0.05).  
EI at 20 Pa was significantly greater post-supplementation in the PUFA group compared to the 
placebo group (PUFA: 0.580 ± 0.003; placebo: 0.574 ± 0.006; p<0.05).  V̇O2 only during the 50% 
trial was significantly greater within the PUFA group post-supplementation compared to pre, 
while no significant differences in V̇O2 were seen between groups at 25%, 50%, or 75% of peak 
power, or at exhaustion.  No significant improvements were seen in time to exhaustion within 
either group and no difference was seen between groups.  CONCLUSION: In acute hypoxia, 
chronic PUFA supplementation significantly, but marginally (1%) improves erythrocyte 
deformability, but does not have a significant effect on oxygen uptake or performance. 
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Chapter 1: Introduction 
 The ability to perform endurance exercise is dependent upon both the ability to 
deliver oxygen to the working muscles and the ability to extract oxygen for oxidative 
metabolism.  Alterations in either of these systems result in decreased endurance 
performance.  Acute exposure to hypoxia has been shown to reduce endurance 
performance, but the mechanisms at the cellular level are still relatively unknown.   
Of the many proposed mechanisms responsible for the decline in performance in 
hypoxia, a reduction in erythrocyte deformability has not been extensively investigated.  
In the capillary, erythrocytes of approximately 8.3µm diameter must deform to be able to 
pass through the rigid capillaries with diameters as small as 3µm (13).  If the erythrocytes 
are unable to properly deform, they do not pass through the capillary to complete the 
transfer of oxygen, and are instead diverted to “accessory channels” (33) resulting in 
regional areas of hypoxia in the muscle tissue.  Reduced erythrocyte deformability has 
been shown in diseased states, such as Type 2 Diabetes, Sickle cell anemia, and Malaria 
Tropica (10).  Additionally, acute exposure to hypoxia, as well as prolonged exercise in 
hypoxia (18), has shown similar results of decreased erythrocyte deformability (31, 36).  
Ultimately, if erythrocyte deformability compromises oxygen delivery (coupled with an 
already reduced arterial content), a larger decrease than expected in maximal oxygen 
uptake (V̇O2max) and performance may be seen in hypoxia.  Similarly, any intervention 
which could increase erythrocyte deformability could hold the potential to mitigate 
V̇O2max and/or performance declines during exercise in hypoxia. 
Chronic supplementation with omega-3 polyunsaturated fatty acids (ω-3 PUFAs) 
has been shown to increase erythrocyte deformability in both humans and animals (5, 
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41).  Mechanistically, ω-3 PUFAs increase the number of unsaturated acyl chains in the 
phospholipid membrane (27) causing total blood viscosity to decrease and erythrocyte 
deformability to increase as a result (27, 41).  Moderate ω-3 PUFA supplementation has 
also been shown to increase V̇O2max in normoxia through the above mechanisms 
described (27).  However, ω-3 PUFAs have yet to be tested to see if they have an effect 
on the decrease in maximal oxygen uptake and exercise performance in hypoxia in highly 
trained endurance athletes. 
Although alterations in blood rheology with chronic ω-3 PUFA supplementation 
have been observed in normoxia, whether or not these changes have any effect in hypoxia 
remains unknown.  If ω-3 PUFA supplementation alters erythrocyte deformability and 
increases the effectiveness of oxygen delivery to the skeletal muscle microvasculature, 
there should be measurable changes in maximal oxygen uptake and/or exercise 
performance in highly trained athletes in hypoxia.  If no changes are seen, then perhaps 
erythrocyte deformability is not a factor limiting endurance exercise in hypoxia. 
Therefore, in this study, we examined V̇O2max and endurance exercise 
performance of highly trained athletes in hypoxia and normoxia pre and post 6-week 
supplementation of ω-3 PUFAs or placebo.   
Hypotheses:   
1. Erythrocyte deformability will be increased after chronic (6 week) ω-3 PUFA 
supplementation. 
2. Performance, measured as TTE, in acute hypoxia will be improved in normoxia 
and hypoxia after chronic ω-3 PUFA supplementation. 
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3. Oxygen consumption at termination of exercise in normoxia and acute hypoxia 
would be increased after chronic ω-3 PUFA supplementation. 
4. Microvascular oxygenation/extraction at termination of exercise in acute hypoxia 
will be increased after chronic ω-3 PUFA supplementation. 
Delimitations:   
This study was delimited to the following: 
1. Fifteen highly trained cyclists with a V̇O2max ≥ 55 mL.kg.-1min-1. 
2. The experimental trials were randomized and blinded for each subject. 
3. Subjects were blinded in regards to which treatment they receive (placebo/omega-
3). 
4. Performance was measured by time to exhaustion at a constant workload. 
5. Subjects performed trials at the same time of day. 
6. Subjects were required to make five visits to the lab: a preliminary V̇O2max test, 
pre-tests in normoxia and hypoxia, and post-tests in normoxia and hypoxia. 
Limitations: 
The data generated from this investigation was interpreted with the following limitations: 
1) Subjects were selectively chosen to be highly trained. 
2) Performance measures could not account for subject motivation.  
3) Subjects will be completing the trials while breathing gas from a facemask 
in a laboratory (normobaric hypoxia) which is markedly different from 
competition/training these athletes may undergo at terrestrial altitude 
(hypobaric hypoxia). 
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4) The findings from this study can only be attributed to a simulated altitude 
of approximately 3000m (9900ft) 
Assumptions:   
This study was based upon the following assumptions: 
1) Subjects represent highly trained endurance athletes in general. 
2) The apparatus used to measure exercise oxygen consumption and ventilation does 
not alter the normal breathing strategies of the athlete.  
3) Simulated altitude correlates with actual altitude. 
4) TTE at a fixed workload is a valid measure of exercise performance. 
5) Motivation to exercise does not change between trials.  
6) Subjects will follow instructions pertaining to pre-exercise behavior, and training 
will remain the same during the supplementation period as the pre-
supplementation period. 
7) Subjects will follow the omega-3 supplementation treatment by ingesting the 
required daily dosage for the entire 6 weeks. 
Statement of the problem: 
Purpose: 
There is tangential evidence of the effects of chronic ω-3 PUFA supplementation 
on endurance exercise performance in hypoxia, but no direct data.  Therefore, the purpose 
of this study was to determine if chronic ω-3 PUFA supplementation improves 
erythrocyte deformability and if any changes are seen, do they result in increased 
microvascular oxygenation, and performance during maximal exercise in acute hypoxia.   
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Definition of Terms 
Endurance trained athletes: Individuals who train regularly for endurance competition 
and have a VO2max ≥ 55 mL/kg/min. 
Erythrocyte deformability: The ability of erythrocytes to alter their shape to pass through 
smaller diameter microvasculature. 
Hypoxia: Decreased partial pressure of oxygen in the ambient environment compared to 
sea level.  When discussing the literature, PIO2 and/or altitude will be given for context. 
Normoxia: Partial pressure of oxygen in the ambient environment at sea level. 
ω-3 PUFA: Omega-3 polyunsaturated fatty acids (see chapter 2 for more detail). 
Oxygen Consumption (V̇O2): The volume of oxygen consumed by the body per 1 minute 
of time (in mL/min). 
POmax: Maximal power output achieved during a VO2max test in normoxia. 
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Chapter 2: Review of Literature 
Effects of Acute Hypoxia on Performance 
 The main characteristic of hypoxia is decreased barometric pressure, which 
concomitantly results in decreased ambient partial pressure of oxygen, leading to a 
reduced partial pressure of inspired oxygen in humans (PIO2) (32).  During rest in 
hypoxia, the inability to compensate for the decrease in PIO2 results in reduced partial 
pressure of oxygen in the alveoli (PAO2).  This reduces the gradient for diffusion between 
the alveoli and capillaries, resulting in a lower partial pressure of oxygen in the arterial 
blood (PaO2) (3, 32, 46).  To prevent SaO2 from decreasing, ventilation needs to be 
increased to maintain PAO2.   
 It is widely accepted that V̇O2max begins to decline at altitudes greater than 
1500m in untrained or moderately trained individuals (3, 32), although it has been shown 
to decrease by as much as 4% at 1250m (40).  Linear relationships have been made 
describing a 10% decrease in V̇O2 per 1000m increase in altitude (32), but there is much 
variability between subjects (7, 26, 42).  Additionally, trained subjects have shown 
significant decreases in V̇O2 at an altitude of 580m, whereas untrained subjects showed 
no decrease (16).  Furthermore, Lawler et al (26) examined the V̇O2 of trained and 
untrained subjects in acute hypoxic exposure of 3000m and found that more aerobically 
fit subjects had a greater reduction in V̇O2max (20.8%) than untrained subjects (10.2%).  
This difference can be contributed to larger declines in SaO2 in the trained subjects.  
Chapman et al (8) examined this relationship and found that the extent of performance 
decline (3000m track time trials in highly trained runners) at altitude was significantly 
related to the drop in SaO2.  Since significant correlations have already been shown 
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between decreased SaO2 and V̇O2max impairment (6, 14, 15), it can be assumed that 
V̇O2max decrements and performance impairments would also be strongly correlated.   
 
Erythrocyte Deformability 
During normal blood flow at rest, blood ejects from the left ventricle into the 
aorta, where it then travels through progressively smaller diameter vessels until it reaches 
the microcirculation.  In the microcirculation, vital exchange of oxygen and carbon 
dioxide occurs between blood and tissues.  In order for this exchange to occur, 
erythrocytes must pass through the smallest vessels of the microcirculation, the 
capillaries.  This poses an issue as normal erythrocyte diameter exceeds 8 µm and it must 
pass through the rigid vessel wall of the capillary that can be as small as 3µm in diameter 
(44).  In order for the erythrocyte to flow through the capillary, it must deform or flex in 
such a way where it is able to fit through the smaller diameter capillary.  This 
phenomenon is referred to as erythrocyte deformability, and can be defined as all of the 
geometric and physical characteristics that allow erythrocytes the ability to pass through 
capillaries with diameters smaller than the erythrocyte itself (44).  Therefore, an 
erythrocyte with high deformability has a greater capacity to pass through small 
capillaries. 
Since capillary flow is bolus flow, that is single file flow of erythrocytes, the 
properties of the flow inside the capillary are rather unique (25).  Canham and Burton (4) 
suggest that one critical factor that affects capillary flow is the minimum cylindrical 
diameter (MCD).  MCD is described as the smallest cylindrical channel through which a 
flexible erythrocyte can pass through without increasing its membrane area.  It has been 
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shown that for normal human erythrocytes, a MCD of approximately 2.8 µm is required 
for a channel 12µm in length (17, 45).  If the channel length is greater than 12µm with a 
MCD of 2.8µm, the channel becomes prohibitive and the erythrocyte only enters partially 
into the channel.  The remainder of the erythrocyte remains outside of the capillary 
incapable of deforming, and can become trapped (25).   
Parthasarathi and Lipowsky (33) explored this mechanism by infusing rats with 
fluorescently labeled rat and human erythrocytes in hypoxia, which has been shown to 
increase regional blood flow and functional capillary density in the microcirculation.  
Erythrocytes were injected into the femoral artery contralateral to the cremaster muscle.  
They found that during the infusion of rat erythrocytes, cardiac output and vascular 
volume increased threefold in hypoxia.  Normalized transit time and tissue hematocrit 
were not significantly different.  During infusion of human erythrocytes, normalized 
transit time and tissue hematocrit decreased significantly (Figures 1 and 2, respectively).  
Cardiac output was increased but vascular volume did not exhibit an increase, suggesting 
that the erythrocytes were redistributed to larger-diameter pathways within the 
microcirculation.  Therefore, if less deformable erythrocytes cannot fit through small 
diameter capillaries, they must be rerouted or they risk becoming trapped in the capillary.   
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Figure 1.  Normalized transit time (TTRBC/TTPI) during bolus infusions of human 
erythrocytes in 5 networks with normal vascular tone.  Transit time decreased 
significantly (P<0.01) because of confinement of human erythrocytes to more centralized 
pathways of network, thus reflecting an attenuation of capillary recruitment (33). 
 
Figure 2.  Microvascular hematocrit (HM) with human erythrocytes perfusing normal tone 
vascular network plotted as a function of PO2.  HM decreased with decreasing PO2, 
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consistent with an attenuated increase in erythrocyte compartment volume. Hence, the 
larger and less deformable human erythrocytes were unable to take advantage of the 
increase in number of pathways generated by hypoxia (33). 
 
Driessen et al (12) found similar results on rats by using the SH-oxidizing agent 
diamide to rigidify erythrocytes.  Erythrocytes were incubated at two concentrations (0.5 
mmol.l-1 and 1.5 mmol.l-1).  After a control period of 30 min, 60-70% of the cells were 
exchanged for the rigidified cells.  Then, they instilled a hypotension period of 30 min by 
bleeding the rats to a pressure of 4.7 kPa.  They found that for the 0.5 mmol.l-1 group, 
erythrocyte velocity decreased from 0.91 mm.s-1 to 0.61 mm.s-1 (30% reduction from the 
control group).  Additionally, during the hypotension period, erythrocyte velocity 
decreased to 0.04 mm.s-1 and flow stoppage was seen in many vessels.  Surprisingly, 
further rigidification of erythrocytes led to a smaller decrease in erythrocyte velocity 
(14% reduction from the control group).  These findings suggest that reduced erythrocyte 
deformability is the primary cause for disturbance of blood flow in the microcirculation, 
especially in the small capillaries. 
Erythrocyte deformability is dependent upon three factors: the maintenance of the 
biconcave shape to maintain a high surface area ratio, normal internal fluidity of the cell, 
and intrinsic membrane deformability (44).  The composition of the phospholipid cell 
membrane has shown to have a large impact on total blood viscosity and erythrocyte 
deformability (5, 41).  When the acyl chains of the membrane phospholipid are 
unsaturated, the lipid fluidity of the erythrocyte membrane increases.  Furthermore, this 
change causes total blood viscosity to decrease and erythrocyte deformability to increase 
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as a result (27, 41).  Weed (44) states that a “decrease in the ratio of surface area to 
volume either by osmotic swelling or by loss of effective surface area will result in 
progressive loss of the biconcave shape and decrease in the ability of the cell to negotiate 
restricted passages within the microcirculation.”  Various chemical agents can alter the 
biconcave shape causing a decrease in surface area (34), including ATP depletion (29).  
Regeneration of ATP reverses this effect. 
Maintenance of the internal fluidity of erythrocytes is regulated by two main 
factors.  First, regulation of appropriate intracellular hemoglobin is needed.  Abnormal 
hemoglobins, such as in sickle cell disease (20) and hemoglobin C disease (9, 28), are 
predisposed to intracellular crystallization resulting in cellular rigidity and reduced 
lifetime.  Furthermore, Heinz body formations (denatured hemoglobin molecules within 
erythrocytes) also cause cellular rigidity and if in great enough numbers, lead to 
premature removal from blood circulation (37).   
Lastly, intracellular ATP, calcium, and magnesium levels in erythrocytes have all 
been determined to be important in maintaining intrinsic membrane deformability (45).  
Weed (44) states that when intracellular calcium reacts with the erythrocyte membrane, 
the membrane becomes very rigid.  This effect can be minimized by intracellular ATP 
binding calcium and magnesium, creating less calcium to react with the membrane.  
Therefore, high intracellular ATP levels are critical in maintaining erythrocyte 
deformability. 
 
Decline of Erythrocyte Deformability at Altitude 
12  
 It is apparent that the human erythrocyte has a great capacity to alter its 
deformability intrinsically.  However, external factors can also play a significant role in 
altering erythrocyte deformability, such as altitude.  La Celle and Weed (24) first 
demonstrated changes in erythrocyte deformability at low oxygen pressures.  In this 
study, deformability was measured as the negative pressure sufficient enough to cause the 
erythrocyte to pass through a 2.9 µm diameter micropipette (Pt), which is similar to the 
MCD found by Canham and Burton (4).  For normal erythrocytes, this is 6.8 mm H2O.  
No reduction in Pt was found with a PO2 as low as 30 mmHg.  However, between 30 and 
20 mmHg PO2, Pt significantly increased to 45 mm H2O, and as PO2 approached zero, Pt 
rose to 500 mm H2O.  When PO2 levels were restored to above 30 mmHg, normal 
deformability was restored.  La Celle and Weed conclude that low levels of PO2 
significantly decrease erythrocyte deformability.   
Continuation of La Celle and Weed’s (24) research has examined the effect of 
hypoxia on erythrocyte deformability at a variety of conditions and in different species as 
well.  Hakim and Macek (19) examined the effect of hypoxia (PO2 = 40-70 mmHg) on 
erythrocyte deformability in various mammalian species.  They concluded that changes in 
deformability are highly species dependent.  A significant decrease in deformability in 
hypoxia was shown in rats, cats, rabbits, and hamsters, but no changes were seen in dogs 
or pigs (Figure 1).  They contribute these findings to species component dependency of 
the hypoxic pressor response (HPR), which is an increase in arterial blood pressure in 
response to hypoxia.  They propose that the HPR has two components: smooth muscle 
contraction (vasoconstriction) and capillary obstruction.  The HPR for a species depends 
on the ratio of these factors.  For example, the results suggest that the HPR in pigs is 
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independent of changes in erythrocyte deformability.  Conversely, the HPR in rats is 
highly dependent upon change in erythrocyte deformability.  Using a similar model, 
Kaniewski et al (23) found a decrease in erythrocyte deformability in rats, but no change 
in cat, dog, human, or rabbit in response to hypoxia (PO2 = 47 ± 6 mmHg, Figure 2).  
Since these studies used in vitro models, we cannot say that changes do not occur in vivo.  
Thus, using animal models to correlate similar effects in humans might not be 
appropriate. 
 
Figure 1. Mean relative filtration time (measure of erythrocyte deformability) during 
normoxic and hypoxic conditions (19). 
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Figure 2.  The maximum elongation index (EImax) in normoxic (empty bars) and hypoxic 
(filled bars) conditions for erythrocytes from cats, dogs, humans, rabbits, and rats (23). 
 
Additionally, variations in methodology have produced conflicting results.  
Hakim and Macek’s (19) results were shown in animals in vivo.  However, Doyle and 
Walker (11) performed similar a similar protocol on rats but instead examined isolated rat 
lungs in vitro.  In line with Hakim and Macek’s findings, they found that a reduction in 
erythrocyte deformability increased the HPR.  Conversely, they found no difference in 
erythrocyte deformability between normoxic and hypoxic conditions.  From this, Doyle 
and Walker concluded that acute hypoxic exposure does not affect erythrocyte 
deformability.  However, it is not entirely known if either of these findings are 
translational to humans.   
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Although animal models have yielded conflicting results, Palareti et al (31) found 
that chronic high altitude exposure during a climbing expedition resulted in the 
deterioration of the rheologic properties of the blood.  Fourteen professional male 
climbers were examined over the course of a 61 day climb to between 5250 and 7350m 
(PIO2 = 53-73 mmHg, Figure 3).  Upon return to normoxia, significant decreases were 
shown in relative viscosity, fibrinogen, platelet count, and erythrocyte deformability.  
Treatment with Pentoxifylline, a pharmaceutical drug shown to decrease blood viscosity, 
was shown to attenuate these decreases, with only platelet count showing a significant 
decrease after the expedition.  In regards to erythrocyte deformability, the authors state 
that when in hypoxia, deoxygenated hemoglobin is increased and thus, may exert a 
binding effect on intracellular ATP in the erythrocyte.  As noted earlier, maintenance of 
intracellular ATP in the erythrocyte is one of the governing factors regulating erythrocyte 
deformability.  Therefore, decreased erythrocyte deformability, due to decreased levels of 
intracellular ATP caused by higher concentration of deoxygenated hemoglobin, might be 
a limiting factor of exercise performance in hypoxia.  To our knowledge, no studies have 
examined this relationship yet.  
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Figure 3.  Altimetric graph of Palareti et al’s climbing expedition (31). 
  
 Acute altitude exposure has also been shown to decrease 
erythrocyte deformability (18).  Fourteen trained subjects were randomized into two 
groups: a control group that ate a “standard diet” consisting of fish and seafood no more 
than once a week, and a treatment group given 6g of ω-3 PUFA daily (18.1% EPA and 
13.6% DHA by weight among other fatty acids; listed in Table 1).  Subjects performed 1 
hour of cycling at an intensity eliciting 70% of their V̇O2max in normoxia and hypoxia 
(simulated altitude of 3000m, PIO2 = 101 mmHg).  Tests were performed pre- and post-
supplementation.  They found that before supplementation in both groups, index of 
filtration I, which increases as erythrocyte deformability decreases, was significantly 
higher after exercise in hypoxia (Figure 4).  Additionally, they found that after 6 weeks of 
ω-3 PUFA supplementation, there was no significant difference in erythrocyte 
deformability between normoxic and hypoxic exercise.  Erythrocyte deformability was 
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significantly decreased in hypoxia in the control group.  Therefore, the results show that 
not only does exercise in hypoxia decrease erythrocyte deformability, but that this 
decrease can be prevented with 6 weeks of ω-3 PUFA supplementation (Figure 5).  The 
authors contribute the decrease in deformability to higher blood levels of ADP/AMP and 
an increase of 2-3 DPG blood concentration.  However, it is not known exactly what fish 
oil affects to cause a change in deformability.   
 
Table 1.  Fatty acid composition of ω-3 PUFAs (18). 
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Figure 4.  Changes in the index of filtration I (red cell suspension pressure/buffer 
pressure) following exercise performed in normoxia and hypoxia in control and MaxEPA 
groups (18). 
19  
 
Figure 5.  Comparison of the index of filtration I of erythrocytes under normoxic 
conditions without MaxEPA, hypoxic conditions without MaxEPA, and hypoxic 
conditions after 6 weeks MaxEPA supplementation (18). 
 
Effect of ω-3 PUFA Supplementation on Erythrocyte Deformability 
 Chronic supplementation with ω-3 PUFAs (specifically eicosapentaenoic acid, 
EPA, and docosahexaenoic acid, DHA) is a possible treatment to increase erythrocyte 
deformability.  While an extensive amount of research has been conducted on this topic, 
there is no data, to our knowledge, examining this treatment in endurance trained athletes.    
 ω-3 PUFAs are fatty acids with a double bond at the third carbon atom from the 
end of the carbon chain and contain at least one other double bond in the carbon chain.  
In humans, ω-3 PUFAs are unable to be synthesized and must come through diet.  The 
most important ω-3 PUFA is α-linolenic acid (18:3ω-3, ALA), which contains 18 carbon 
atoms with 3 double bonds and is sourced from plants, seeds, and nuts.  ALA is 
considered an essential fatty acid because other ω-3 PUFAs can be synthesized from it, 
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such as eicosapentaenoic acid (20:5ω-3, EPA) and docosahexaenoic acid (22:6ω-3, 
DHA).  EPA and DHA play an important role in a number of physiological processes and 
can also be absorbed through the diet from seafood and marine oils.    
Early research examining the effects of ω-3 PUFA supplementation on 
erythrocyte deformability yielded promising results.  Terano et al (41) examined 8 
healthy adult males before and after 4 weeks of supplementation of EPA (3.6g EPA/day).  
They found no change in plasma viscosity, a decrease in whole blood viscosity, and an 
increase in erythrocyte deformability following supplementation (Figure 6).  
Additionally, there was a positive correlation between erythrocyte deformability and EPA 
content in the phospholipid membrane of erythrocytes (Figure 7).  Cartwright et al [8] 
found the same results using a similar protocol.  They examined 5 healthy adult males 
before, after 3 weeks, and after 6 weeks of omega-3 EPA supplementation (3.4g 
EPA/day).  Erythrocyte deformability was significantly increased after 3 and 6 weeks of 
EPA supplementation (Figure 8), resulting in a reduction in whole blood viscosity.  Since 
plasma viscosity was unaffected by supplementation, the increase in erythrocyte 
deformability was responsible for the decrease in whole blood viscosity.  Also, the 
viscoelastic properties of the erythrocyte membrane are dependent upon EPA content.  
Therefore, EPA supplementation represents an effective way to increase the elasticity and 
deformability of erythrocytes. 
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Figure 6.  Erythrocyte deformability (VRBC) before and after 4 weeks of EPA 
supplementation (41). 
 
Figure 7.  Correlation between erythrocyte deformability (VRBC) and EPA content in 
erythrocyte phospholipids (41). 
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Figure 8.  Erythrocyte deformability, expressed as red cell filtration rate (mm·H2O/s), 
before (week 0) and after 3 and 6 weeks EPA supplementation (5). 
 
 Although some studies have shown an increase in erythrocyte deformability 
following ω-3 PUFA supplementation, a number of studies have shown no such change.  
Rillaerts et al (38) gave 20 men with coronary heart disease 6 weeks of ω-3 PUFA 
supplementation (0.9g EPA, 0.6g DHA).  Following supplementation, there was no 
change in erythrocyte deformability, as shown by a lack of decrease in whole blood 
viscosity and erythrocyte viscosity.  The lower amount of fish oil given (1.5g total 
compared to 3.6g and 3.4g in the Terano (41) and Cartwright (5) studies, respectively) 
could explain the differences in the results shown.  However, Blonk et al (2) found no 
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significant difference in erythrocyte deformability following 12 weeks of 
supplementation with 1.5g, 3.0g, and 6.0g of ω-3 PUFAs, despite finding a dose-response 
increase in the amount of ω-3 PUFAs incorporated into the phospholipid membrane.  
Oostenbrug et al (30) and Ho et al (22) showed the same results following 3 weeks and 
12 weeks of ω-3 PUFA supplementation, respectively.  With the lack of consistency in 
the methodology, namely the supplementation amount, length, and measurement for 
erythrocyte deformability, the results are conflicting.  It is evident that further research, 
using a standard procedure for measuring erythrocyte deformability and supplementation 
length, is needed to create reproducible studies to allow for fair comparisons.   
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Chapter 3: Methodology  
The purpose of this study was to determine the effect of chronic ω-3 PUFA 
supplementation on skeletal muscle oxygenation, oxygen uptake, and endurance exercise 
performance in highly trained cyclists.  This study utilized a placebo controlled mixed 
model design, with ω-3 PUFA treatment as a between group factor and pre/post treatment 
as a within groups factor.  Primary dependent variables were erythrocyte elongation 
index (EI), oxy/deoxy/total-hemoglobin and myoglobin (Hb+Mb; from near infared 
spectroscopy, NIRS), exercise metabolic measures, and time to exhaustion at a power 
output equal to 75% of POmax. 
Subjects:  The study was performed on highly trained cyclists (n=13; sample size 
from power analysis of (18, 43)).  Inclusion criteria for the highly trained cyclists 
included indication on a questionnaire that they considered themselves to be an 
endurance trained individual and a V̇O2max greater than 55 ml.kg-1.min-1.  Exclusion 
criteria for all subjects included: current smoker or smoking history in the last 12 months, 
history of hypertension, cardiovascular, or pulmonary disease, musculoskeletal or other 
existing health condition which preclude participation in physical activity, abnormal ECG 
or blood pressure response to physical activity based on the maximal cycle ergometry 
test, resting systolic BP > 130 mmHg and resting diastolic BP > 90 mmHg, women who 
are or believe they could be pregnant, who are post-menopausal, or who are taking birth 
control or hormone replacement therapy, known allergy to ω-3 or ω-6 PUFAs, fish intake 
> 1 serving per week, fish oil or omega-3 supplementation over the previous 4 weeks, 
and BMI > 32 kg/m2. 
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Study Design:  On five separate days, subjects were asked to report to the 
laboratory to complete testing protocol.  On Day 1, subjects were asked to complete the 
informed consent form at the Human Performance Laboratory.  Subjects then performed 
a maximal oxygen uptake exercise test on a cycle ergometer.  Subject candidates were 
informed of their eligibility to continue their participation in the study (V̇O2max > 55 
mL.kg-1.min-1).  Days 2 and 3 used the same testing procedures.  Subjects were asked to 
complete a submaximal cycle ergometry exercise test (explained in detail later).  Subjects 
breathed either normoxic (room) air or hypoxic (15% O2) air for exercise trials, 
randomized between days.  After Day 3, subjects underwent supplementation for six 
weeks (explained in following section).  Then, on Days 4 and 5 subjects followed the 
same testing procedures as Days 2 and 3. 
Treatment:  Subjects were pair matched by age and baseline EI, and then 
randomized into ω-3 PUFA and placebo treatment groups.  The ω-3 PUFA treatment 
consisted of a daily dose of 8 gel capsules totaling 2g of (DHA), 3g of (EPA), and 100mg 
of Vitamin E, taken daily for 6 weeks (Table 2).  This dosage and supplementation 
duration has been shown in healthy subjects to improve both brachial arterial blood flow 
during forearm exercise (43) and erythrocyte deformability (18).  The placebo groups 
were given iso-caloric doses (matching the ω-3 PUFA doses) of safflower oil capsules, an 
ω-6 PUFA shown not to affect erythrocyte deformability or endothelial function (Table 
3).  Subjects were asked to continue their exercise training as normal throughout the 
duration of the study.  Additionally, subjects were asked to provide training logs for 6 
weeks prior to participating in the study, as well as during the duration of the study.  
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Subjects were asked to keep a daily supplement diary and to return the supplement diary, 
medication containers, and unused pills at their final testing session. 
Fatty Acid Weight % 
4:0 0 
6:0 0 
8:0 0.5 
10:0 0.3 
12:0 0 
14:0 0.4 
14:1 0 
15:0 0 
16:0 2.8 
16:1 1.1 
18:0 3.7 
18:1 10.3 
18:2ω-6 1.2 
18:3ω-6 0.2 
18:3ω-3 0.7 
18:4ω-3 1.8 
20:0 0.4 
20:1 2.5 
20:2ω-6 0.3 
20:3ω-6 0.3 
20:4ω-6 0.2 
20:3ω-3 1.6 
20:4ω-3 1.5 
20:5ω-3 36.5 
22:0 0.2 
22:1 1.8 
22:2ω-6 0 
22:4ω-6 0 
22:5ω-6 0.7 
22:5ω-3 4.1 
22:6ω-3 26.3 
24:0 0 
24:1 0.5 
Table 2.  Fatty acid composition of ω-3 supplement.  The fatty acid composition is 
described with the following notation X:Yω-B 
X: the number of carbon atoms 
Y: the number of double bonds 
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B: the position of double bonds from the terminal carbon 
Fatty Acid Weight % 
4:0 0 
6:0 0 
8:0 1.2 
10:0 0.1 
12:0 0 
14:0 0.1 
14:1 0 
15:0 0 
16:0 10.8 
16:1 0.1 
18:0 2.8 
18:1 23.9 
18:2ω-6 53.8 
18:3ω-6 0 
18:3ω-3 5.5 
18:4ω-3 0 
20:0 0.2 
20:1 0.2 
20:2ω-6 0 
20:3ω-6 0 
20:4ω-6 0 
20:3ω-3 0 
20:4ω-3 0 
20:5ω-3 0 
22:0 0.3 
22:1 0 
22:2ω-6 0 
22:4ω-6 0 
22:5ω-6 0 
22:5ω-3 0.9 
22:6ω-3 0 
24:0 0 
24:1 0 
Table 3.  Fatty acid composition of placebo supplement.  The fatty acid composition is 
described with the following notation X:Yω-B 
X: the number of carbon atoms 
Y: the number of double bonds 
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B: the position of double bonds from the terminal carbon 
Exercise Protocols 
Maximal Oxygen Uptake Cycle Ergometry Exercise Test:  This test measures the 
maximal rate of oxygen uptake, and is often referred to as a V̇O2max test.  This test was 
performed on an electronically braked cycle ergometer (Velotron, RacerMate Inc., 
Seattle, WA), where the resistance was automatically adjusted, depending on the pedaling 
cadence the subject used, to equal the set workload.  During the test, subjects were fitted 
with a fingertip pulse oximeter, heart rate monitor, NIRS sensor, and oro-nasal face 
mask.  All testing equipment was adjusted to maximize subject comfort.  The test began 
with the subject pedaling at a self-selected cadence between 60 and 100 rpm.  The 
workload started at 75W and increased 25W every minute.  The test ended when the 
subject could no longer maintain the required power output or the subject voluntarily 
stopped (volitional fatigue).  Following the test, subjects were allowed to cool down for 
up to 10 minutes, pedaling at a self-selected intensity. 
Cycle ergometry test:  Subjects performed three exercise trials on a cycle 
ergometer.  Each trial consisted of 3 min of cycling at 25%, 50%, and 75% of POmax, 
with each workload preceded by 1 min of unloaded pedaling (to control for any NIRS 
movement artifact).  Between trials, subjects rested for 5 minutes.  In the 75% trial, after 
the 3rd minute subjects continued at this workload until they were unable to maintain 
power output (fall under 60 rpm) or volitional exhaustion.  Time to exhaustion was 
recorded.  
Hypoxic inspirate:  Submaximal cycle exercise protocols were performed in 
normoxia and normobaric hypoxia (inspired O2 fraction 15%; equivalent to an altitude of 
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3000m / 9900ft at typical barometric pressure of Bloomington, IN).  Subjects were 
blinded to the inspirate, and the order of the inspirate was randomized and 
counterbalanced between Days 2-3 and Days 4-5.  The hypoxic inspirate was delivered 
from pre-mixed gas cylinders into a 100 L balloon reservoir, attached to the inspired side 
of a Hans Rudolph face mask.   Fractional oxygen content of each tank was verified by 
mass spectrometry by the manufacturer and was verified in our laboratory using a 
metabolic cart (Vmax Encore Metabolic Cart, CareFusion Corporation, San Diego, CA).  
Subjects breathed the inspirate for 10 minutes at rest prior to the initial cycle exercise 
workloads, during the complete exercise bout, and during all rest periods between bouts.  
Arterial oxyhemoglobin saturation was continuously monitored with fingertip pulse 
oximetry (Model PC-68A, Shenzen Creative Industry Co, Ltd., Shenzen, China).   
Near-infrared Spectroscopy (NIRS):  NIRS (ISS Model 96208, ISS, Inc., 
Champaign, IL) was used in vivo to non-invasively determine the volume of heme-O2 
carriers in the exercising muscle microcirculation.  Prior to testing, the NIRS sensor was 
calibrated at two different wavelengths of near-infrared light using a manufacture 
provided calibration block.  For the submaximal cycle exercise trials, the NIRS sensor 
was placed on the surface of the right vastus lateralis (15 cm proximal from the middle of 
the proximal border of the patella, then 5 cm lateral).  Device probes were secured with a 
Velcro strap and wrapped with a cloth bandage to prevent movement and light leakage.  
Position of the device probe was marked with indelible marker and photographed to 
match placement between trials. 
Metabolic measures:  For all trials, subjects were fitted with a face mask (#2700, 
Hans Rudolph Inc., Shawnee, KS) attached to a two-way non-rebreathing valve.  
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Ventilation and expired gas concentrations were continuously measured, with these 
variables and oxygen uptake measured on a breath by breath basis.   
Erythrocyte deformability:  Ektacytometry (RheoScan-D300, Sewon Meditech, 
Inc., Seoul, Korea) was used to measure the elongation index (EI) of erythrocytes before 
and after exercise.  EI measurements from the RheoScan-D300 have been validated in the 
literature (39).  This device required only 5 µL of blood for processing; therefore finger 
prick capillary samples were collected.  Finger prick samples were collected at rest and 
immediately following the cycle exercise protocol.  Therefore, on each of Days 2, 3, 4, 
and 5, each subject gave 2 finger prick samples, for a total of 8 for the entire study.  Prior 
to testing, the ekyacytometer was calibrated using an internal calibration procedure. 
 Statistical analysis:  This study utilized multiple 2 x 2 split plot, repeated 
measures ANOVAs with time (pre, post) as the within subject variable and treatment (ω-
3 or placebo) as the between subject variable.   Separate ANOVAs were utilized for each 
dependent variable of interest.  Tests of a priori simple main effects were used to 
determine differences in pre- and post- measures within each treatment group.  An alpha 
of p<0.05 was used to indicate statistical significance. 
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 Chapter 4: Results 
Subject Characteristics 
Table 4.  Subject Characteristics 
Characteristics ω-3 PUFA Placebo 
Age (years) 20.3 ± 1.4 21.1 ± 2.4 
Mass (kg) 78.9 ± 7.3 76.1 ± 6.4 
Height (cm) 177.6 ± 7.7 180.5 ± 4.0 
V̇O2max (mL.kg-1.min-1) 60.2 ± 4.5 67.3 ± 2.9 
Sex  5M, 1F 7M 
Values are presented as mean ± SD. 
Erythrocyte Deformability 
In hypoxia, post-exercise elongation index was significantly increased from pre- 
to post-supplementation in the ω-3 PUFA group at 17 Pa (pre: 0.512 ± 0.006; post: 0.519 
± 0.004) and 20 Pa (pre: 0.574 ± 0.004; post: 0.580 ± 0.003) of shear stress (Table 5).  No 
significant pre/post-supplementation differences were seen at any of the other shear 
stresses within either experimental group.  Post-exercise elongation index in the ω-3 
PUFA group was significantly greater than placebo following supplementation at 20 Pa, 
but no significant differences between groups were seen at any of the other shear stresses.   
In normoxia, there were no significant differences from pre- to post-
supplementation in elongation index within either group at any shear stress (Table 6).  
Additionally, there were no significant differences in elongation index between groups at 
any shear stress in normoxia. 
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Table 5.  Elongation Index in hypoxia, post-exercise. 
 2 Pa 3 Pa 4 Pa 5 Pa 6 Pa 7 Pa 
 Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
ω-3 PUFA 0.205 ± 0.022 
0.219 ± 
0.026 
0.270 ± 
0.022 
0.281 ± 
0.023 
0.305 ± 
0.011 
0.310 ± 
0.011 
0.320 ± 
0.006 
0.323 ± 
0.007 
0.330 ± 
0.005 
0.333 ± 
0.006 
0.340 ± 
0.005 
0.344 ± 
0.006 
Placebo 0.213 ± 0.039 
0.209 ± 
0.026 
0.273 ± 
0.030 
0.274 ± 
0.032 
0.305 ± 
0.015 
0.306 ± 
0.018 
0.331 ± 
0.008 
0.320 ± 
0.010 
0.331 ± 
0.008 
0.331 ± 
0.008 
0.343 ± 
0.009 
0.342 ± 
0.008 
 8 Pa 10 Pa 12 Pa 15 Pa 17 Pa 20 Pa 
 Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
ω-3 PUFA 0.353 ± 0.006 
0.357 ± 
0.006 
0.382 ± 
0.006 
0.388 ± 
0.007 
0.416 ± 
0.007 
0.423 ± 
0.007 
0.472 ± 
0.006 
0.480 ± 
0.006  
0.512 ± 
0.006 
†0.519 ± 
0.004 
0.574 ± 
0.004 
*† 0.580 
± 0.003  
Placebo 0.356 ± 0.011 
0.355 ± 
0.009 
0.387 ± 
0.013 
0.385 ± 
0.009 
0.421 ± 
0.013 
0.419 ± 
0.009 
0.477 ± 
0.011 
0.475 ± 
0.008 
0.516 ± 
0.009 
0.514 ± 
0.007 
0.576 ± 
0.004 
0.574 ± 
0.006 
Pre/Post-supplementation Elongation Index at various shear stresses following experimental trials in hypoxia.   
Note: Values are presented as mean ± SD. 
Pa, Pascals of shear stress. 
* denotes significant difference between groups (P < 0.05).   
† denotes significant difference in pre/post-supplementation measurements (P < 0.05).   
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Table 6.  Elongation Index in normoxia, post-exercise. 
 2 Pa 3 Pa 4 Pa 5 Pa 6 Pa 7 Pa 
 Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
ω-3 PUFA 0.214 ± 0.033 
0.214 ± 
0.030 
0.275 ± 
0.025 
0.277 ± 
0.024 
0.307 ± 
0.012 
0.308 ± 
0.012 
0.321 ± 
0.007 
0.321 ± 
0.007 
0.332 ± 
0.007 
0.332 ± 
0.006 
0.343 ± 
0.008 
0.343 ± 
0.006 
Placebo 0.219 ± 0.041 
0.212 ± 
0.018 
0.278 ± 
0.030 
0.277 ± 
0.014 
0.308 ± 
0.014 
0.308 ± 
0.007 
0.322 ± 
0.008 
0.322 ± 
0.003 
0.333 ± 
0.008 
0.332 ± 
0.003 
0.344 ± 
0.009 
0.342 ± 
0.004 
 8 Pa 10 Pa 12 Pa 15 Pa 17 Pa 20 Pa 
 Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
ω-3 PUFA 0.356 ± 0.010 
0.356 ± 
0.007 
0.386 ± 
0.011  
0.386 ± 
0.009 
0.420 ± 
0.012 
0.420 ± 
0.009 
0.476 ± 
0.010 
0.475 ± 
0.009 
0.515 ± 
0.008 
0.513 ± 
0.009 
0.576 ± 
0.003 
0.572 ± 
0.009 
Placebo 0.358 ± 0.011 
0.355 ± 
0.004 
0.389 ± 
0.012 
0.385 ± 
0.005 
0.423 ± 
0.012 
0.419 ± 
0.006 
0.478 ± 
0.010 
0.476 ± 
0.005 
0.516 ± 
0.007 
0.516 ± 
0.004 
0.574 ± 
0.004 
0.578 ± 
0.003 
Pre/Post-supplementation Elongation Index at various shear stresses following experimental trials in normoxia.   
Note: Values are presented as mean ± SD. 
Pa, Pascals of shear stress. 
* denotes significant difference between groups (P < 0.05).   
† denotes significant difference in pre/post-supplementation measurements (P < 0.05).   
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Figure 1.  Individual subject pre/post-supplementation elongation index at 20 Pa of shear stress in hypoxia in ω-3 PUFA and placebo 
groups.  * denotes significant difference between pre- and post-supplementation (P < 0.05).   
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Oxygen Consumption 
No significant differences were seen in V̇O2 during the post- supplementation 
25%, 75%, and TTE trials in hypoxia between the ω-3 PUFA (Figure 2) and placebo 
groups (Figure 3).  In the post-supplementation 50% trial in hypoxia, the ω-3 PUFA 
group had a significantly higher V̇O2 (post: 40.9 ± 2.8 mL.kg.min-1; pre: 38.2 ± 3.6 
mL.kg.min-1).  Conversely, V̇O2 during the post-supplementation 50% trial in hypoxia in 
the placebo group was significantly lower (post: 38.5 ± 4.4 mL.kg.min-1; pre: 41.7 ± 4.7 
mL.kg.min-1).   
During post-supplementation exercise trials in hypoxia, no significant differences 
in V̇O2 were seen between groups at any workload (Figure 4).  Additionally, no 
significant differences in V̇O2 were seen between or within groups during post-
supplementation exercise trials in normoxia (Figure 5).   
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Figure 2.  Oxygen Consumption during exercise in hypoxia 
corresponding to 25%, 50% and 75% of POmax in ω-3 PUFA group 
pre- and post-supplementation. 
*denotes significant difference in pre/post-supplementation  
measurements (P < 0.05). 
Figure 3.  Oxygen Consumption during exercise in hypoxia 
corresponding to 25%, 50% and 75% of POmax in Placebo group 
pre- and post-supplementation. 
*denotes significant difference in pre/post-supplementation 
measurements (P < 0.05). 
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Figure 4.  Post-supplementation oxygen consumption between groups 
during exercise in hypoxia corresponding to 25%, 50% and 75% of 
POmax. 
Figure 5.  Post-supplementation oxygen consumption between 
groups during exercise in normoxia corresponding to 25%, 50% and 
75% of POmax. 
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Time to Exhaustion 
No significant difference was seen in pre- or post-supplementation time to exhaustion 
at 75% of POmax between groups in hypoxia (Figure 6) or normoxia (Figure 7).  
Furthermore, no significant difference was seen between pre- and post-supplementation time 
to exhaustion within groups in hypoxia or normoxia (Table 7). 
 Time to Exhaustion (sec) 
 Pre-Normoxia Post-Normoxia  Pre-Hypoxia Post-Hypoxia 
ω-3 PUFA 860 ± 176 902 ± 165  358 ± 83 354 ± 82 
Placebo 652 ± 200 719 ± 251  344 ± 59 357 ± 113 
Table 7.  Pre- and post-supplementation time to exhaustion at 75% of POmax during exercise 
trials in hypoxia and normoxia. 
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Figure 6.  Pre- and post-supplementation time to exhaustion at 75% of 
POmax in ω-3 PUFA and placebo groups during exercise trials in 
hypoxia. 
Figure 7.  Pre- and post-supplementation time to exhaustion at 75% of 
POmax in ω-3 PUFA and placebo groups during exercise trials in normoxia. 
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Chapter 5: Discussion 
 The aim of this study was to examine the degree to which six weeks of ω-3 PUFA 
supplementation alters erythrocyte deformability, and if any such changes alter oxygen 
uptake and time to exhaustion in normoxia and normobaric hypoxia.  The primary findings 
were that 6 weeks of ω-3 PUFA supplementation (1) significantly but marginally increased 
erythrocyte deformability in hypoxia, but not in normoxia, (2) increased V̇O2 during cycling 
only at 50% of POmax in hypoxia, but no other workloads or conditions, and (3) did not 
result in any change in time to exhaustion in normoxia or hypoxia. 
Erythrocyte Deformability 
 Erythrocyte deformability has been shown to decrease at low oxygen pressures (24), 
after chronic high altitude exposure (31), and after hypoxic exercise (18) in humans, but 
animal models have not yielded the same results (11, 19, 23).  Inconsistent methodology in 
these data makes it difficult to reach concrete conclusions of these results.  Prior to 
ektacytometry, there was no standard for measuring and reporting erythrocyte deformability, 
therefore, each of the previous studies measured and reported deformability differently.  La 
Celle measured the negative pressure required to cause an erythrocyte to enter a 2.9µm 
micropipette (24).  Guezennec used the suspension technique and measured deformability as 
the erythrocyte suspension/buffer pressure ratio (18).  Palareti (31) measured filtration time 
of erythrocytes passed through a 5 µm filter at 20 cm/H2O pressure, where they were filtered 
at 37°C, compared to room temperature in the Guezennec study.  Doyle (11) and Hakim (19) 
both measured filtration time through a 4.7 µm membrane, but did not report the pressure at 
which erythrocytes passed through the membrane.  Kaniewski used a very similar 
ektacytometry protocol as the one used in this study (23).  Although the current method of 
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measuring erythrocyte deformability is ektacytometry, the Kaniewski study remains one of 
the few studies that have collected deformability data in this manner.  Therefore, interpreting 
our results with previous studies using different methodologies may not be appropriate.   
To our knowledge, this is the first study to examine the effect of acute hypoxic 
exercise on erythrocyte deformability, using the current method of ektacytometry.  We found 
that chronic ω-3 PUFA supplementation significantly, but marginally (1%) increases 
erythrocyte deformability after acute hypoxic exercise, consistent with previous literature 
using different methodology to measure deformability (18).  However, these results (along 
with no change in deformability in normoxia) did not have a significant effect on endurance 
exercise performance, suggesting that increased erythrocyte deformability of this small 
magnitude is not likely a limiting factor in endurance performance in highly trained athletes.  
Despite hypothesizing that deformability would be increased in both hypoxia and 
normoxia, our data showed no change in normoxia and a marginal increase (1%) in hypoxia.  
It was thought that a significant increase in erythrocyte deformability with chronic omega-3 
supplementation would lead to less resistive capillary blood flow, thereby increasing the rate 
at which erythrocytes could enter and pass through the capillaries, and as a result, improving 
oxygen delivery.  Although each subject in the omega-3 group increased their deformability 
at 20 Pa shear stress in hypoxia (Figure 1), deformability was not different at lower shear 
stresses or at any shear stress in normoxia.  This, combined with no significant change in 
V̇O2 or time to exhaustion, suggests that chronic omega-3 supplementation does not increase 
erythrocyte deformability in highly-trained endurance athletes at a physiologically relevant 
shear stress.  If deformability was increased at a physiologically relevant range of shear 
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stresses during exercise, we would expect to see changes in V̇O2 and time to exhaustion.  
However, no such changes were seen.   
Therefore, chronic ω-3 PUFA supplementation may have no practical effect on 
erythrocyte deformability or there may be something unique to endurance athletes that results 
in no change.  Weed (44) states that erythrocyte deformability is dependent upon three main 
factors: 1) maintenance of biconcave shape to maintain high surface area ratio, 2) normal 
internal fluidity of cell, and 3) intrinsic membrane deformability.  Normal internal fluidity of 
the erythrocytes is dependent upon intracellular hemoglobin and intrinsic membrane 
deformability is dependent intracellular ATP.  Since we know that endurance athletes have 
increased hemoglobin mass compared to untrained populations (21), and generate more ATP 
at higher V̇O2 (1), endurance training itself may “max out” deformability, to where it cannot 
increase any further.  Our data showing only a marginal increase in deformability at very 
high shear stress in hypoxia support this claim.  If endurance training itself increases 
deformability, then it is likely that erythrocyte deformability would play no significant role in 
limiting exercise performance in endurance trained athletes.    
Although our data suggest a marginal 1% change in erythrocyte deformability is not 
large enough to affect endurance exercise performance, further research in this area is 
needed.  There is a lack of data in four key areas.  (1) More data is needed examining the 
effect of omega-3 supplementation on erythrocyte deformability in untrained individuals to 
fully support the previous claim about endurance athletes.  (2) Our study is one of a handful 
of studies that has examined erythrocyte deformability in trained endurance athletes (18, 30, 
35).  Most previous research was performed using animal models (11, 19, 23) or used 
outdated filtration techniques (18).  It is relatively unknown how trained athletes’ erythrocyte 
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deformability compares to other, more researched populations.  Of the studies examining 
erythrocyte deformability in relation to performance (30, 35), there is both a lack of 
homogeneity and variety in the methodology in regards to the exercise being performed.  
Including this study, all three studies have attempted to examine endurance performance, but 
have all used different exercise modes and intensities (30, 35).  Furthermore, sprint based, 
anaerobic exercise events have not been studied.  (4) Although the effect of hypoxia on 
erythrocyte deformability has been examined (11, 19, 23, 24, 31), its effect specifically in 
relation to exercise performance has not been extensively researched (18).  With a growing 
number of trained athletes competing and training at altitude, mitigating any negative effects 
is crucial for optimal athletic performance. 
Oxygen Consumption 
 Our data suggest that following ω-3 PUFA supplementation, oxygen consumption is 
significantly increased at submaximal, but unchanged at near maximal workloads in hypoxia, 
and unchanged at all workloads in normoxia.  Our data show that V̇O2 is significantly higher 
post-supplementation in the ω-3 PUFA group during cycling in hypoxia at 50% of POmax.  
This finding is difficult to interpret.  Since these subjects were performing the same workload 
during both tests, a higher oxygen consumption suggests that they were less economical, 
given they required more oxygen to perform the same workload.  Since the trial at 50% of 
POmax occurred submaximally, if the increase in deformability increased O2 delivery, we 
would expect O2 extraction to change proportionally and for V̇O2 to remain the same.  Since 
no change was seen in V̇O2 at exhaustion, the change in deformability likely had no effect on 
O2 delivery, and the difference in V̇O2 at 50% of POmax was likely due to changes in 
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economy.  Due to the short duration (3 min) that the subjects cycled for at this workload, it 
remains difficult to draw a conclusion from the evidence present.   
Normoxic V̇O2max has been shown to increase following ω-3 PUFA supplementation 
(27), but Oostenbrug et al (30) found no change in mean V̇O2 during a fixed workload test in 
normoxia.  Despite Oostenbrug et al’s subjects supplementing for 3 weeks compared to 6 
weeks in this study, both studies showed no significant change in normoxic V̇O2.  This 
suggests that increasing erythrocyte deformability through ω-3 PUFA supplementation is not 
beneficial for increasing oxygen consumption in normoxia.  Further investigation examining 
longer duration exercise in hypoxia is needed to determine a conclusion in hypoxia. 
Performance 
 Our finding that time to exhaustion was not improved in normoxia following ω-3 
PUFA supplementation lines up with previous research (30, 35).  Although erythrocyte 
deformability was not measured in these studies, our data showing no change in 
deformability in normoxia following supplementation suggest that their subjects likely did 
not see any increase in deformability.  Although increasing deformability, in theory, should 
allow for greater O2 delivery, it does not appear that chronic supplementation with a large 
dose of ω-3 PUFAs (5g/day) can cause enough of an increase in deformability in endurance 
trained athletes to result in significant performance benefits in normoxia.  Thus, erythrocyte 
deformability is not likely a limiting factor during endurance exercise in normoxia. 
 Unlike normoxia, acute hypoxic exposure, as well as prolonged exercise in hypoxia, 
has been shown to decrease erythrocyte deformability (18).  Although a lack of data exist 
relating this to performance, we hypothesized that this decreased deformability has a 
negative effect on endurance performance.  Therefore, increasing deformability through ω-3 
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PUFA supplementation could result in improved endurance performance.  However, our 
results showed no change in time to exhaustion in hypoxia following supplementation in the 
ω-3 PUFA group, despite an increase in deformability.  These data suggest that the modest 
increase in erythrocyte deformability with chronic omega-3 supplementation is not a factor in 
mitigating the decline in endurance exercise performance in normobaric hypoxia.   
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Conclusion 
 Although six weeks of ω-3 PUFA supplementation significantly, but marginally 
increased erythrocyte deformability (1%), this resulted in no beneficial improvements in time 
to exhaustion performance or oxygen uptake.  5g/day of omega-3s produced a modest 
increase in deformability, but does not appear to be enough of a change to improve 
performance in trained endurance athletes.    
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Supplemental Materials 
Appendix 1.  Subject Characteristic data. 
 
SubjectID Supplement Age Sex Height (cm) Weight (kg) V̇O2max 
(mL/kg/min) 
Max Power 
(W) 
1015 Omega-3 20 M 183.0 82.1 68.6 450 
1017 Omega-3 18 M 175.5 72.5 61.7 350 
1020 Omega-3 20 F 168.7 68.0 56.8 300 
1021 Placebo 19 M 184.8 84.2 67.9 450 
1022 Omega-3 21 M 177.4 84.2 57.4 325 
1024 Placebo 21 M 180.6 71.1 67.1 375 
1027 Placebo 21 M 178.7 72.2 69.6 375 
1029 Omega-3 21 M 171.2 79.3 56.9 375 
1033 Placebo 22 M 182.9 80.7 70.2 425 
1034 Omega-3 22 M 189.5 87.1 59.8 475 
1035 Placebo 19 M 186.8 86.9 67.6 400 
1036 Placebo 20 M 183.6 76.3 67.2 400 
1037 Placebo 26 M 175.1 72.1 61.4 300         
Omega-3 Mean   20.3 
 
177.55 78.87 60.20 379.2 
Omga-3 Sdev 
 
1.4 
 
7.69 7.29 4.54 69.7 
Placebo Mean   21.1 
 
181.79 77.64 67.29 389.3 
Placebo Sdev 
 
2.4 
 
3.97 6.36 2.86 47.6 
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Appendix 2.  Time to exhaustion, HR, and V̇O2 data. 
SubjectID PrNTTE PrHTTE PNTTE PHTTE PrNHR PrHHR PNHR PHHR PrNV25 PrHV25 PNV25 PHV25 
1015 1035 482 793 349 - - - - 23.98 24.52 22.88 21.74 
1017 565 267 723 463 - - - - 25.03 27.12 23.85 24.95 
1020 1023 430 1200 434 - - - - 22.48 24.87 20.17 25.31 
1021 896 254 738 246 - - - - 25.83 24.10 23.56 21.91 
1022 804 363 848 294 179 174 185 - 24.04 20.10 21.68 26.04 
1024 540 368 707 332 193 180 182 169 28.20 28.50 25.40 28.50 
1027 456 326 553 224 188 179 185 168 30.53 33.12 30.37 25.90 
1029 927 303 927 335 174 174 - 176 24.05 20.98 24.10 21.51 
1033 965 447 1261 541 - 179 181 - 28.37 25.67 25.49 31.03 
1034 807 305 918 247 200 188 190 169 23.27 22.79 22.99 26.56 
1035 485 345 540 464 185 - 194 - 29.78 24.14 25.29 20.44 
1036 626 313 641 351 185 185 185 - 24.95 22.77 23.54 22.72 
1037 593 355 590 338 188 182 174 174 21.63 22.89 20.87 24.04              
Omega-3 Mean 860.2 358.3 901.5 353.7 184.3 178.7 187.5 172.5 23.81 23.40 22.61 24.35 
Omga-3 Sdev 175.9 83.3 165.2 82.1 13.8 8.1 3.5 4.9 0.86 2.62 1.47 2.19 
Placebo Mean 651.6 344.0 718.6 356.6 187.8 181.0 183.5 170.3 27.04 25.88 24.93 24.93 
Placebo Sdev 200.2 58.7 250.5 112.8 3.3 2.5 6.5 3.2 3.11 3.74 2.90 3.78 
Pr Pre-supplementation 
P Post-supplementation 
N Normoxia 
H Hypoxia 
TTE Time To Exhaustion (sec) 
HR Heart Rate (bpm) 
V25 V̇O2 (mL/kg/min) during last 30 sec of 25% trial 
V50 V̇O2 (mL/kg/min) during last 30 sec of 50% trial 
V75 V̇O2 (mL/kg/min) during last 30 sec of 75% trial 
V75TTE V̇O2 (mL/kg/min) during last 30 sec of Time to Exhaustion trial 
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SubjectID PrNV50 PrHV50 PNV50 PHV50 PrNV75 PrHV75 PNV75 PHV75 PrNV75TTE PrHV75TTE PNV75TTE PHV75TTE 
1015 38.99 41.95 41.78 42.49 61.68 59.21 61.80 62.30 71.70 65.62 72.75 66.13 
1017 46.50 42.84 43.46 45.07 71.06 57.64 59.91 62.00 66.21 61.38 68.80 61.63 
1020 37.76 35.23 35.70 38.14 48.79 47.16 49.23 50.81 55.38 53.14 52.18 53.71 
1021 43.73 38.67 42.22 37.29 61.89 54.68 62.03 54.99 62.58 56.94 67.74 57.88 
1022 34.30 34.02 35.94 39.06 48.90 50.55 48.36 53.43 41.20 33.00 27.23 52.55 
1024 46.70 47.30 41.80 46.60 65.90 66.10 65.50 70.60 68.80 66.10 65.50 70.60 
1027 45.98 47.48 44.56 41.59 65.00 59.67 63.95 59.35 71.34 66.06 75.57 60.61 
1029 39.95 37.01 40.70 38.29 58.42 52.64 59.31 49.10 62.75 52.28 59.02 54.97 
1033 45.39 42.66 41.46 35.08 58.31 59.77 64.86 41.45 69.01 62.83 69.15 38.99 
1034 38.10 38.08 40.10 42.08 58.40 54.48 59.96 60.17 60.76 58.04 52.73 61.38 
1035 47.28 42.16 42.76 34.29 51.32 46.46 61.11 48.90 39.41 32.39 61.25 55.06 
1036 42.06 39.11 41.34 38.84 58.64 51.40 57.07 51.75 61.74 55.45 54.90 54.67 
1037 30.49 34.55 31.89 35.49 41.32 49.95 46.46 48.22 47.98 51.31 50.02 50.85              
Omega-3 Mean 39.27 38.19 39.61 40.86 57.88 53.61 56.43 56.30 59.67 53.91 55.45 58.40 
Omga-3 Sdev 4.03 3.56 3.15 2.80 8.39 4.48 5.98 5.89 10.56 11.41 16.15 5.42 
Placebo Mean 43.09 41.70 40.86 38.45 57.48 55.43 60.14 53.61 60.12 55.87 63.45 55.52 
Placebo Sdev 5.84 4.71 4.10 4.38 8.64 6.81 6.67 9.36 12.01 11.76 8.76 9.62              
Pr Pre-supplementation 
P Post-supplementation 
N Normoxia 
H Hypoxia 
TTE Time To Exhaustion (sec) 
HR Heart Rate (bpm) 
V25 V̇O2 (mL/kg/min) during last 30 sec of 25% trial 
V50 V̇O2 (mL/kg/min) during last 30 sec of 50% trial 
V75 V̇O2 (mL/kg/min) during last 30 sec of 75% trial 
V75TTE V̇O2 (mL/kg/min) during last 30 sec of Time to Exhaustion trial 
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Appendix 3.  Elongation index data in normoxia. 
   
Pre-Supplementation Elongation Index in Normoxia   
Shear Stress (Pa) 
SubjectID Supplement 0.5 1 1.5 2 2.5 3 4 5 
1015 Omega-3 0.000049 0.007036 0.120780 0.183152 0.215518 0.249197 0.293950 0.313530 
1017 Omega-3 0.000041 0.006637 0.123509 0.183965 0.216403 0.250435 0.294754 0.313772 
1020 Omega-3 -0.000415 0.124083 0.187103 0.224515 0.261305 0.288149 0.313863 0.324713 
1021 Placebo 0.000023 0.004186 0.107309 0.181390 0.213273 0.247994 0.293626 0.312790 
1022 Omega-3 -0.000389 0.039028 0.159170 0.198176 0.233352 0.265104 0.302861 0.318976 
1024 Placebo 0.000444 0.026034 0.157178 0.196634 0.232939 0.265404 0.302959 0.318837 
1027 Placebo 0.000101 0.012988 0.142800 0.190371 0.225224 0.258477 0.299051 0.316412 
1029 Omega-3 -0.000430 0.120602 0.187800 0.224550 0.261267 0.288209 0.313990 0.324722 
1033 Placebo -0.001135 0.159136 0.209146 0.250057 0.284204 0.304385 0.320456 0.328549 
1034 Omega-3 -0.005563 0.178507 0.223847 0.269012 0.297623 0.311407 0.322653 0.331780 
1035 Placebo -0.002199 0.168749 0.214933 0.258309 0.290525 0.307869 0.321442 0.329801 
1036 Placebo -0.009542 0.188851 0.233469 0.278003 0.303335 0.314430 0.323546 0.332460 
1037 Placebo 0.000025 0.004537 0.110006 0.180386 0.213051 0.247975 0.293573 0.313084  
Omega-3 Mean -0.001118 0.079316 0.167035 0.213895 0.247578 0.275417 0.307012 0.321249  
Omega-3 Sdev 0.002189 0.071662 0.040392 0.032718 0.031882 0.024653 0.011648 0.007150  
Placebo Mean -0.001755 0.080640 0.167834 0.219307 0.251793 0.278076 0.307808 0.321705  
Placebo Sdev 0.003555 0.086439 0.051608 0.041263 0.039271 0.029600 0.013525 0.008348 
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Pre-Supplementation Elongation Index in Normoxia   
Shear Stress (Pa) 
SubjectID Supplement 6 7 8 10 12 15 17 20 
1015 Omega-3 0.324906 0.335565 0.347531 0.376125 0.409686 0.466412 0.507359 0.572481 
1017 Omega-3 0.325014 0.335785 0.347946 0.376912 0.410685 0.467335 0.507952 0.572143 
1020 Omega-3 0.334103 0.345190 0.358233 0.388844 0.423431 0.479560 0.518701 0.579018 
1021 Placebo 0.323998 0.334820 0.347085 0.376216 0.409922 0.465869 0.505571 0.567670 
1022 Omega-3 0.329341 0.339863 0.351949 0.380890 0.414712 0.471613 0.512543 0.577453 
1024 Placebo 0.329430 0.340395 0.352971 0.382785 0.417238 0.474601 0.515522 0.579935 
1027 Placebo 0.327396 0.338338 0.350751 0.380137 0.414146 0.470855 0.511341 0.575098 
1029 Omega-3 0.333945 0.344864 0.357743 0.388041 0.422313 0.477949 0.516738 0.576486 
1033 Placebo 0.337978 0.349827 0.363649 0.395129 0.429445 0.483114 0.519351 0.573550 
1034 Omega-3 0.343494 0.357506 0.373058 0.406630 0.441456 0.493521 0.527386 0.576413 
1035 Placebo 0.340162 0.352925 0.367476 0.399795 0.434218 0.486924 0.521887 0.573372 
1036 Placebo 0.344386 0.358620 0.374300 0.407786 0.442112 0.492806 0.525426 0.572201 
1037 Placebo 0.324846 0.336258 0.349106 0.379402 0.414325 0.472291 0.513502 0.578146  
Omega-3 Mean 0.331801 0.343129 0.356077 0.386240 0.420381 0.476065 0.515113 0.575666  
Omega-3 Sdev 0.007018 0.008195 0.009508 0.011347 0.011813 0.010096 0.007539 0.002765  
Placebo Mean 0.332599 0.344455 0.357905 0.388750 0.423058 0.478066 0.516086 0.574282  
Placebo Sdev 0.008127 0.009266 0.010515 0.012106 0.012183 0.009724 0.006728 0.004020 
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Post-Supplementation Elongation Index in Normoxia   
Shear Stress (Pa) 
SubjectID Supplement 0.5 1 1.5 2 2.5 3 4 5 
1015 Omega-3 -0.000387 0.061465 0.171642 0.206609 0.242771 0.273466 0.307224 0.321152 
1017 Omega-3 -0.000336 0.125292 0.184146 0.220469 0.256808 0.284424 0.312118 0.323711 
1020 Omega-3 -0.000750 0.145009 0.199300 0.239603 0.275211 0.298111 0.318058 0.327552 
1021 Placebo -0.001401 0.160339 0.209479 0.251703 0.285429 0.304808 0.320331 0.328795 
1022 Omega-3 0.000017 0.003017 0.087659 0.176146 0.206879 0.241300 0.289751 0.311072 
1024 Placebo 0.000102 0.013530 0.142969 0.188893 0.223811 0.257067 0.298051 0.316018 
1027 Placebo -0.000234 0.101940 0.174345 0.211085 0.247456 0.277149 0.309028 0.322135 
1029 Omega-3 -0.000194 0.063518 0.161801 0.200197 0.235724 0.267108 0.303938 0.319554 
1033 Placebo -0.000616 0.140008 0.196533 0.235602 0.271974 0.296238 0.317466 0.326754 
1034 Omega-3 -0.000251 0.048983 0.159638 0.198204 0.233663 0.265386 0.302933 0.318887 
1035 Placebo -0.000240 0.082655 0.171576 0.208160 0.244203 0.274400 0.307673 0.321489 
1036 Placebo -0.000841 0.137847 0.197247 0.236669 0.273066 0.296812 0.317263 0.326468 
1037 Placebo 0.000063 0.011091 0.147439 0.191864 0.227145 0.260953 0.300517 0.316754  
Omega-3 Mean -0.000459 0.084775 0.165866 0.213904 0.248485 0.276529 0.307589 0.321383  
Omega-3 Sdev 0.000554 0.068240 0.044784 0.029109 0.030070 0.024319 0.011847 0.006835  
Placebo Mean -0.000330 0.083720 0.172654 0.211683 0.247604 0.276864 0.308403 0.321720  
Placebo Sdev 0.000300 0.047119 0.018717 0.017868 0.018293 0.014489 0.006753 0.003775 
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Post-Supplementation Elongation Index in Normoxia   
Shear Stress (Pa) 
SubjectID Supplement 6 7 8 10 12 15 17 20 
1015 Omega-3 0.330916 0.341506 0.353888 0.383497 0.417811 0.474969 0.515734 0.579877 
1017 Omega-3 0.332978 0.343544 0.355878 0.384793 0.417453 0.470330 0.507066 0.563409 
1020 Omega-3 0.337374 0.349326 0.363218 0.395032 0.430054 0.485490 0.523344 0.580576 
1021 Placebo 0.338786 0.351163 0.365433 0.397577 0.432305 0.486225 0.522428 0.576324 
1022 Omega-3 0.323115 0.334198 0.346545 0.375818 0.409864 0.466797 0.507481 0.571550 
1024 Placebo 0.327353 0.338336 0.350530 0.378870 0.411165 0.464191 0.501500 0.559396 
1027 Placebo 0.331550 0.341909 0.354059 0.383083 0.416603 0.472152 0.511558 0.573211 
1029 Omega-3 0.329716 0.340188 0.352320 0.381550 0.415880 0.473932 0.515896 0.582784 
1033 Placebo 0.336008 0.347422 0.360894 0.392247 0.427252 0.483356 0.522066 0.581142 
1034 Omega-3 0.329148 0.339613 0.351683 0.380696 0.414716 0.472142 0.513579 0.579498 
1035 Placebo 0.331153 0.341599 0.353801 0.382986 0.416816 0.473150 0.513298 0.576405 
1036 Placebo 0.335873 0.347449 0.361024 0.392365 0.427075 0.482267 0.520083 0.577419 
1037 Placebo 0.327393 0.338442 0.351143 0.381189 0.415716 0.472765 0.513162 0.576292  
Omega-3 Mean 0.331754 0.343012 0.355915 0.385931 0.419775 0.474667 0.512926 0.571855  
Omega-3 Sdev 0.005954 0.006456 0.007278 0.008693 0.009426 0.009395 0.008958 0.008798  
Placebo Mean 0.331549 0.342375 0.354989 0.384874 0.419151 0.475681 0.515663 0.578107  
Placebo Sdev 0.003295 0.003650 0.004211 0.005153 0.005516 0.004920 0.003950 0.003257 
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Appendix 4.  Elongation index data in hypoxia. 
   
Pre-Supplementation Elongation Index in Hypoxia   
Shear Stress (Pa) 
SubjectID Supplement 0.5 1 1.5 2 2.5 3 4 5 
1015 Omega-3 -0.000766 0.027799 0.152989 0.194972 0.229449 0.261571 0.300869 0.317627 
1017 Omega-3 -0.000251 0.116204 0.178505 0.214835 0.251306 0.280305 0.310441 0.322725 
1020 Omega-3 -0.000191 0.065107 0.163705 0.201415 0.236472 0.267600 0.304180 0.319583 
1021 Placebo 0.000006 0.001170 0.047479 0.169269 0.198005 0.231919 0.284935 0.308138 
1022 Omega-3 -0.000622 0.136355 0.194869 0.234154 0.270465 0.294940 0.316994 0.326974 
1024 Placebo -0.000224 0.131942 0.180857 0.216207 0.252085 0.280823 0.310662 0.322549 
1027 Placebo 0.000021 0.003647 0.097123 0.177742 0.208968 0.243440 0.290840 0.311651 
1029 Omega-3 0.000333 0.028156 0.161869 0.199055 0.235766 0.267799 0.303851 0.319188 
1033 Placebo 0.000024 0.003480 0.083772 0.172046 0.203471 0.236962 0.286405 0.309431 
1034 Omega-3 -0.002097 0.165647 0.212256 0.255720 0.288608 0.306597 0.320773 0.329256 
1035 Placebo 0.000119 0.012127 0.136376 0.187799 0.221390 0.254532 0.296905 0.315236 
1036 Placebo -0.000436 0.136767 0.192102 0.230108 0.266569 0.292258 0.315890 0.325801 
1037 Placebo -0.005530 0.181716 0.226291 0.270982 0.298946 0.312207 0.322962 0.332003  
Omega-3 Mean -0.000341 0.079763 0.153067 0.205142 0.239630 0.269526 0.304680 0.319599  
Omega-3 Sdev 0.000291 0.057175 0.053719 0.022191 0.024854 0.021776 0.011183 0.006451  
Placebo Mean -0.001081 0.075934 0.158541 0.213350 0.246245 0.273399 0.305375 0.320367  
Placebo Sdev 0.002126 0.081412 0.055478 0.039219 0.038583 0.030486 0.014732 0.008824 
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Pre-Supplementation Elongation Index in Hypoxia   
Shear Stress (Pa) 
SubjectID Supplement 6 7 8 10 12 15 17 20 
1015 Omega-3 0.327965 0.338225 0.349998 0.378366 0.411751 0.468255 0.509085 0.574090 
1017 Omega-3 0.331963 0.342418 0.354765 0.384265 0.418263 0.474484 0.514306 0.576544 
1020 Omega-3 0.329473 0.339619 0.351374 0.379715 0.412963 0.468997 0.509325 0.573281 
1021 Placebo 0.320490 0.331788 0.344529 0.374910 0.410045 0.467974 0.508714 0.571799 
1022 Omega-3 0.336670 0.348353 0.361985 0.393451 0.428388 0.484152 0.522500 0.580850 
1024 Placebo 0.331339 0.341347 0.353262 0.381925 0.415089 0.470012 0.508916 0.569676 
1027 Placebo 0.323730 0.335064 0.347743 0.377816 0.412824 0.471555 0.513709 0.580435 
1029 Omega-3 0.329874 0.341100 0.353917 0.383952 0.418223 0.474574 0.514337 0.576289 
1033 Placebo 0.321965 0.332762 0.344539 0.372692 0.406125 0.463431 0.505305 0.572672 
1034 Omega-3 0.339625 0.352392 0.366973 0.399450 0.434154 0.487482 0.522975 0.575403 
1035 Placebo 0.326122 0.336528 0.348291 0.376452 0.409499 0.465294 0.505512 0.569373 
1036 Placebo 0.334848 0.345806 0.358778 0.389231 0.423539 0.478970 0.517454 0.576500 
1037 Placebo 0.343789 0.357942 0.373675 0.407677 0.442998 0.495895 0.530361 0.580344  
Omega-3 Mean 0.329650 0.340292 0.352652 0.382105 0.416083 0.472312 0.512141 0.574373  
Omega-3 Sdev 0.005371 0.005434 0.005772 0.006401 0.006665 0.006268 0.005503 0.003915  
Placebo Mean 0.331422 0.343085 0.356274 0.386753 0.421052 0.476743 0.515665 0.575859  
Placebo Sdev 0.008277 0.009422 0.010827 0.012889 0.013487 0.011740 0.009024 0.003960 
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Post-Supplementation Elongation Index in Hypoxia   
Shear Stress (Pa) 
SubjectID Supplement 0.5 1 1.5 2 2.5 3 4 5 
1015 Omega-3 -0.000322 0.142139 0.190298 0.227673 0.263752 0.290173 0.315490 0.326040 
1017 Omega-3 -0.000305 0.049488 0.163841 0.201395 0.236875 0.268230 0.304616 0.319975 
1020 Omega-3 -0.000797 0.145501 0.199911 0.239933 0.275740 0.298664 0.318264 0.327389 
1021 Placebo -0.000461 0.129799 0.189845 0.227521 0.264155 0.290303 0.314868 0.325348 
1022 Omega-3 -0.000739 0.146059 0.200718 0.240742 0.276367 0.299221 0.318825 0.327975 
1024 Placebo 0.000012 0.002303 0.078038 0.174072 0.204935 0.240242 0.289609 0.310807 
1027 Placebo 0.000002 0.000393 0.014970 0.132624 0.180598 0.209561 0.268594 0.299661 
1029 Omega-3 -0.000403 0.093574 0.179792 0.217097 0.254472 0.283226 0.312084 0.323978 
1033 Placebo -0.000357 0.112275 0.184548 0.221234 0.257921 0.285693 0.312997 0.324098 
1034 Omega-3 -0.002290 0.170383 0.215156 0.258572 0.290697 0.307786 0.320888 0.328982 
1035 Placebo -0.000488 0.115710 0.187155 0.224980 0.262025 0.288831 0.314189 0.324724 
1036 Placebo 0.000250 0.018506 0.149107 0.191825 0.226641 0.259690 0.299985 0.317048 
1037 Placebo -0.000728 0.090001 0.183103 0.219446 0.256954 0.285034 0.312318 0.323619  
Omega-3 Mean -0.000435 0.102548 0.170442 0.218556 0.253637 0.281139 0.310279 0.322922  
Omega-3 Sdev 0.000301 0.061502 0.047197 0.026023 0.027824 0.022973 0.011352 0.006581  
Placebo Mean -0.000573 0.085835 0.159119 0.209397 0.247044 0.274260 0.305865 0.320301  
Placebo Sdev 0.000823 0.058667 0.066401 0.039082 0.034720 0.031785 0.017559 0.009751 
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Post-Supplementation Elongation Index in Hypoxia   
Shear Stress (Pa) 
SubjectID Supplement 6 7 8 10 12 15 17 20 
1015 Omega-3 0.335183 0.346102 0.359055 0.389694 0.424541 0.481433 0.521312 0.583061 
1017 Omega-3 0.330130 0.340691 0.352922 0.382266 0.416547 0.474185 0.515640 0.581391 
1020 Omega-3 0.336950 0.348726 0.362494 0.394154 0.429098 0.484505 0.522384 0.579711 
1021 Placebo 0.334705 0.345836 0.358909 0.389450 0.423764 0.479114 0.517499 0.576338 
1022 Omega-3 0.337566 0.349384 0.363212 0.395046 0.430229 0.486104 0.524362 0.582350 
1024 Placebo 0.322979 0.334534 0.347532 0.378233 0.413594 0.472056 0.513418 0.577951 
1027 Placebo 0.314658 0.326174 0.338456 0.367856 0.402442 0.460139 0.500916 0.564118 
1029 Omega-3 0.333469 0.344403 0.357279 0.387772 0.422604 0.479777 0.520048 0.582695 
1033 Placebo 0.333133 0.343709 0.356236 0.385940 0.419806 0.475158 0.513958 0.573999 
1034 Omega-3 0.339204 0.351890 0.366398 0.398686 0.433124 0.485909 0.520956 0.572605 
1035 Placebo 0.333829 0.344606 0.357287 0.386988 0.420403 0.474284 0.511602 0.568701 
1036 Placebo 0.327664 0.338269 0.350428 0.379601 0.413789 0.471477 0.513089 0.579268 
1037 Placebo 0.333025 0.343977 0.356820 0.386935 0.420931 0.476007 0.514336 0.573265  
Omega-3 Mean 0.332919 0.344212 0.357354 0.388141 0.422962 0.479566 0.519103 0.580134  
Omega-3 Sdev 0.005527 0.005646 0.006036 0.006643 0.006671 0.005589 0.004247 0.002623  
Placebo Mean 0.330712 0.341861 0.354701 0.384825 0.419014 0.474679 0.513558 0.573522  
Placebo Sdev 0.007828 0.007973 0.008555 0.009367 0.009311 0.007915 0.006602 0.006191 
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Appendix 5.  Informed Consent Form.  
INDIANA UNIVERSITY INFORMED CONSENT STATEMENT FORM 
 
The effects of altered erythrocyte deformability on microvasculature oxygenation and exercise tolerance in adults 
with type 2 diabetes 
 
You are invited to participate in a research study that will help determine the effects of omega-3 fatty acid 
(fish oil) supplementation on how you complete an exercise task.  You were selected as a possible subject 
because you identified that you were either:  a) a type 2 diabetic,  b) an individual who does not regularly 
engage in training / physical activity, or c) a highly endurance trained individual.  We ask that you read this 
form and ask any questions you may have before agreeing to be in the study.  
 
Disclaimer:  It is possible that you will not qualify for the study following the completion of the blood test, 
height, weight, or maximal exercise test. 
 
The study is being conducted by Robert F. Chapman, Ph.D. (Principal Investigator), Timothy Mickleborough, 
PhD, Chad Wiggins, and Josh Foss in the Department of Kinesiology at Indiana University-Bloomington, and 
Kieren Mather, MD of the Department of Medicine at Indiana University.  This study is funded by a 2013 
American Diabetes Association Innovation Award. 
 
 
STUDY PURPOSE 
 
The purpose of the proposed study is to investigate how six weeks of omega-3 fatty acid (fish oil) 
supplements affects your ability to complete various exercise tasks.   
 
 
NUMBER OF PEOPLE TAKING PART IN THE STUDY: 
 
If you agree to participate, you will be one of 60 subjects who will be participating in this research. 
 
 
PROCEDURES FOR THE STUDY: 
 
If you agree to be in the study, the following items are included: 
 
An invitation will be extended to visit the Human Performance laboratory a total of 6 times over a time period 
of approximately 10-12 weeks.  Each visit will be done at a previously agreed-upon time.  The first two visits 
last about 60 minutes and the remaining four visits last about 75 minutes.  You should refrain from drinking 
caffeine for at least 8 hours prior to your visit.  If you are an endurance trained athlete, you should refrain 
from exhaustive exercise (exercise that causes significant fatigue) for 24 hours prior to each visit.  If you are 
an untrained individual (completing less than 90 minutes of physical activity a week), we ask that you 
maintain the same low level of physical activity throughout the study. 
 
Visit #1 
This visit includes a blood draw to measure your blood cholesterol, blood glucose, and hemoglobin values.   
 
Visit #2 
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This visit includes the following tests: a) measures of your height, weight, resting pulse, and resting blood 
pressure, and b) a maximal exercise test on a stationary bicycle.   
 
Visits #3 through #6 
These visits include the following tests:  a) a forearm handgrip test (i.e. repeated squeezing against a 
resistance), and b) a submaximal exercise test on a stationary bicycle.  For these tests, you will either breathe 
room air or low oxygen air, simulating an altitude of approximately 9,900 feet, which is equivalent to an 
altitude you might experience in the Rocky Mountains. 
 
Between Visits #4 and #5, you will be asked to take capsules that are omega-3 (fish oil) supplements or 
placebos (capsules of safflower oil that look like the fish oil supplement).  You will take 8 capsules a day, 4 in 
the morning and 4 in the evening, each day for 6 weeks (42 consecutive days).  You will be asked to record 
the date and time you take your capsules on a supplement diary sheet, which we will provide you.  You may 
also record any comments you may have on this sheet.  You will be asked to return the supplement diary 
sheet, the supplement containers, and any unused pills with your final visit to the lab (Visit #6). 
 
 
Each of the tests and supplement routine is described below. 
 
Blood draw (visit #1 only).   A small amount of blood will be collected to measure your cholesterol, glucose, 
and hemoglobin levels.  For this test, the inside of your arm, opposite your elbow will be swabbed with 
alcohol and a sterile needle will be briefly inserted.  A small amount of blood (about 4 teaspoons) will be 
collected into a tube for analysis. 
 
Height, weight, heart electrical activity, and blood pressure measures.  Height will be measured by asking 
you to stand against a wall and a device will be lowered until it touches the top of your head.  Weight will be 
measured by having you sit on a chair, which is placed on a scale.  Blood pressure will be measured by 
placing a cuff around your upper arm.  The cuff will be inflated, squeezing your upper arm, and quickly 
deflated.  Adhesive electrodes will be placed on your chest and wires attached to monitor the electrical 
activity of your heart.   
 
Maximal Cycle Exercise Test (visit #2 only).  This exercise test will be completed on a stationary bicycle.  
Resting measurements will be collected for 5 minutes and followed by a 5 minute warm-up at a pace you 
select.  The test begins with cycling at between 70 - 100 rpm with a light resistance load.  Every minute, a 
small amount of additional resistance will be added until you can no longer maintain the required power 
output.  The goal is for you to exercise for as long as you can, and for most individuals, this is about 8-12 
minutes of pedaling.   
 
Forearm Handgrip Test (visits #3 through #6 only).  For this test, you will be asked to lie down on a 
padded table with your dominant arm (the arm you use to throw a ball) held out away from your side, resting 
on a table.  You will be asked to wrap your fingers around a handgrip device, which is similar to a handle on a 
suitcase.  You will be asked to squeeze the handle as hard as you can 3 times, resting between each squeeze.  
You will then be asked to perform 3 different exercise bouts of repeated squeezing.  Repeated squeezing will 
be 5 seconds of squeezing and 5 seconds of relaxing.  An audio recording will tell you when to squeeze and 
when to relax.  The first two exercise bouts of repeated squeezing will be for 3 minutes, separated by 5 
minutes of rest.  The first bout will be at a low effort (17% of your maximal squeeze force) and the second at 
a medium effort (33% of maximal squeeze force).  The third and last bout of repeated squeezing will be at 
50% of your maximal squeeze force, done for as long as you can, or until your force falls to less than 33% of 
your maximal squeeze force for 3 consecutive squeezes.  Normally, this third bout of repeated squeezing lasts 
about 4 to 7 minutes. You will be able to view a monitor that tells how hard you are squeezing and what 
target you are trying to achieve. 
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Submaximal Cycle Exercise Test (visits #3 through #6 only).  This exercise test will be completed on a 
stationary bicycle.  You will be asked to complete 3 separate cycle exercise efforts lasting 3 minutes each, 
separated by 10 minutes of seated rest.  Each of the cycle exercise efforts will be at progressively higher 
resistances, equal to 25%, 50%, and 75% of the peak resistance you achieved in the maximal cycle test.  For 
each of the 3 cycle exercise efforts, resting measurements will be collected for 5 minutes and followed by a 5 
minute warm-up at a very light resistance.  You will be able to view a screen that shows the time completed.   
 
All of the exercise tests (maximal cycle exercise, forearm handgrip, and submaximal cycle exercise) include 
wearing a clip that shines light through your index finger, either adhesive electrodes on your chest or a 
wireless heart rate monitor strap, and breathing either through a rubber mouthpiece while wearing nose clips, 
or a face mask which covers your nose and mouth.  Either room air or low oxygen air simulating an altitude 
of approximately 9,900ft will flow into and out of your lungs as you breathe through the mouthpiece or face 
mask. You will not be told which air (room air or low oxygen air) you will be given.  Rubber mouthpieces, 
face masks, heart rate monitor, and nose clips are cleansed in a detergent and antibacterial solution following 
each use.   During each forearm exercise test, a fiber optic cable bundle will be secured by elastic bandages to 
your exercising forearm (about 1/3rd of the distance from your elbow to your wrist).  During the submaximal 
cycle exercise test, a fiber optic cable bundle will be secured by elastic bandages to your left thigh and left 
calf.  This device uses light waves to measure the oxygen content of your tissues. 
 
Finger prick blood samples.  Prior to the first exercise effort and immediately after each exercise effort of 
the forearm handgrip and submaximal cycle exercise test, we will prick your fingertip with a sterile needle 
and collect a few drops of blood.  This means on each of Visits #3 through #6, you will receive a total of 8 
finger pricks. 
  
 
RISKS OF TAKING PART IN THE STUDY: 
 
While on the study, the risks are: 
 
Both maximal and moderate level exercise tests of healthy individuals, as described by the American College 
of Sports Medicine, presents little risk to the subject and does not require medical clearance for subjects under 
40.  For untrained and type 2 diabetic subjects, men over 45 years of age and women over 55 years of age, the 
risks associated with exercise testing increases.  Potential risks and/or discomforts can include episodes of 
temporary light-headedness, chest discomfort, leg or arm cramps, occasional irregular heartbeats, and 
abnormal blood pressure responses.  The risk of heart attack, although minor, (approximately 1 to 2 in 
10,000) does exist, and a heart attack could result in death.  During exercise testing you will be closely 
monitored for any abnormal changes in heart rate or breathing.  You are free to indicate any discomfort and 
discontinue participation at any time. 
 
There is a slight risk of skin discomfort or irritation from the fiber optic bundles and electrodes that will be 
placed on your skin.  
 
There is a risk of blood pooling in your legs and low blood pressure immediately following the cycle exercise 
tests.  After the tests, you will be allowed to cool down on the exercise bike.  If at any time during testing you 
become light headed, you may have to lie down until you feel normal. 
 
Risks associated with taking blood include excessive bleeding, fainting or feeling lightheaded, and possible 
infection.  All blood samples will be taken by qualified individuals.  A reasonable effort will be made to 
minimize the risks associated with drawing blood through the use of proper procedures and sterile techniques.   
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Potentially negative side effects could occur while taking the supplements.  Common side effects include 
vomiting, nausea, bloating and burping. Rare side effects consist of easy bleeding/bruising and serious 
allergic reaction. 
 
Breathing low oxygen air involves the risk of lightheadedness, heavy breathing, dry throat, and irritation of 
nasal passages due to the dry nature of the gas used. 
 
In type 2 diabetic subjects, there is a risk of hypoglycemia (low blood sugar).  
 
There is a potential risk of loss of confidentiality. 
 
 
BENEFITS OF TAKING PART IN THE STUDY: 
 
The benefits to participation that are reasonable to expect are information regarding your cholesterol and 
glucose levels, overall level of fitness, and how omega-3 fatty acid (fish oil) supplements may help you 
tolerate exercise better.  Other than this information, you will gain little benefit.  All subjects will be provided 
with feedback concerning their own results and the general findings of the study upon request. 
 
CONFIDENTIALITY 
 
Efforts will be made to keep your personal information confidential.  Data will be stored on password 
protected computers in locked rooms with limited public access.  We cannot guarantee absolute 
confidentiality.  Your personal information may be disclosed if required by law.  Your identity will be held in 
confidence in reports in which the study may be published and databases in which results may be stored. 
 
Organizations that may inspect and/or copy your research records for quality assurance and data analysis 
include groups such as the study investigator and his/her research associates, the American Diabetes 
Association, the IU Institutional Review Board or its designees, and (as allowed by law) state or federal 
agencies, specifically the Office for Human Research Protections (OHRP) and the U.S. Food and Drug 
Administration (FDA), who may need to access the collected medical and/or research data. 
 
 
PAYMENT 
 
You will be paid a total of $150 for completing all (6) days of testing.  Payment will be made by check and 
will be delivered by postal mail within approximately 4 weeks of your final testing session.  If you withdraw 
prior to completing all days of testing, you will be paid according the exercise trial(s) you complete or attempt 
to complete; $30 per exercise trial (Visits 2-6).   
 
 
COMPENSATION FOR INJURY 
 
In the event of physical injury resulting from your participation in this research, necessary medical treatment 
will be provided to you at your own expense.  Costs not covered by your health care insurer will be your 
responsibility.  Also, it is your responsibility to determine the extent of your health care coverage.  There is no 
program in place for other monetary compensation for such injuries.  However, by signing this form you are 
not giving up any legal rights or benefits to which you are otherwise entitled. 
 
 
CONTACTS FOR QUESTIONS OR PROBLEMS 
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For questions about the study or a research-related injury, contact the researcher Robert Chapman, Ph.D. at 
(812) 856-2452 or rfchapma@indiana.edu.  If you cannot reach the researcher during regular business hours 
(i.e. 8:00AM-5:00PM), please call the IU Human Subjects Office at (812) 856-4242 or (800) 696-2949.   
 
For questions about your rights as a research participant or to discuss problems, complaints or concerns about 
a research study, or to obtain information, or offer input, contact the IU Human Subjects Office at (812) 856-
4242 or (800) 696-2949. 
 
 
VOLUNTARY NATURE OF STUDY 
 
Taking part in this study is voluntary.  You may choose not to take part or may leave the study at any time.  
Leaving the study will not result in any penalty or loss of benefits to which you are entitled.  Your decision 
whether or not to participate in this study will not affect your current or future relations with the investigators 
or Indiana University. 
 
Your participation may be terminated by the investigator without regard to your consent in the following 
circumstances: blood pressure, ECG, cholesterol, height and weight, or maximal exercise test results that do 
not meet the criteria for inclusion in the study, an abnormal response to exercise testing, or an inability to 
complete the exercise tests. 
 
 
SUBJECT’S CONSENT 
 
In consideration of all of the above, I give my consent to participate in this research study.   
 
I will be given a copy of this informed consent document to keep for my records.  I agree to take part in this 
study. 
 
 
Subject’s Printed Name:________________________________________________ 
 
Subject’s Signature:____________________________________________________Date:_______________ 
        (must be dated by the subject) 
 
 
Printed Name of Person Obtaining Consent:  
 
Signature of Person Obtaining Consent: Date:____________ 
 
 
 
   For IRB Office Use ONLY  IRB Approval Date:   
Expiration Date:  
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Appendix 6.  Modified Physical Activity Readiness Questionnaire (PAR-Q). 
Modified Physical Activity Readiness Questionnaire (PAR-Q) 
Name Date 
DOB Age Home Phone Work Phone 
Regular exercise is associated with many health benefits, yet any change of activity may increase the risk of injury. 
Please read each question carefully and answer every question honestly: 
Yes No 1. Has your doctor ever said that you have a heart condition and that you should only do physical activity recommended by a doctor? 
Yes No 2. Do you feel pain in your chest when you do physical activity? 
Yes No 3. In the past month, have you had chest pain when you were not doing physical activity? 
Yes No 4. Do you lose your balance because of dizziness or do you ever lose consciousness? 
Yes No 5. Do you have a bone or joint problem that could be made worse by a change in your physical activity? 
Yes No 6. Is your doctor currently prescribing drugs (for example, water pills) for your blood pressure or heart condition? 
Yes No 7. Do you know of any other reason you should not do physical activity? 
Yes No 8. Has your doctor ever told you that you have diabetes?  
Yes No 9. Has your doctor ever told you that you have high blood pressure?  
Yes No 10. Has your doctor ever told you that you have high cholesterol?  
Yes No 11. Has your doctor ever told you that you have high blood sugar?  
Yes No 12. Do you smoke? 
Yes No 13. Are you currently inactive?  
Yes No 14. Do you have a father, brother or son with heart disease before the age of 55 years old or a mother, sister or daughter with heart disease before the age of 65 years old? 
15. Measure height and weight to determine BMI:        16. Measure resting BP and pulse 
Height:________                                                                 BP:_______________  Pulse:____________ 
Weight:________                                                           
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Participant Signature Date 
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Appendix 7.  General Study Questionnaire. 
 
General Study Questionnaire 
Name Date 
 
On average over the last 8 weeks, how many minutes per 
week did you exercise? 
 
Do you consider yourself to be a highly endurance trained 
individual? 
(Circle one)                   YES                         NO 
  
 
Participant Signature Date 
 
 
Food Frequency Questionnaire from: Hanson JA, Lin Y, Strandjord SE, and Hibbeln JR. The Relationship between Omega-3 HUFA Score and Dietary Intake of EPA and DHA among 
U.S. Soldiers. Journal of the Academy of Nutrition and Dietetics 113: A26, 2013 
IRB study #1307011736 
 
Appendix 8.  Omega-3 Food Frequency Questionnaire. 
Omega-3 Food Frequency Questionnaire 
 
 
 
 
Department of Kinesiology 
 
Human Performance Laboratory 
Indiana University 
Food Frequency Questionnaire from: Hanson JA, Lin Y, Strandjord SE, and Hibbeln JR. The Relationship between Omega-3 HUFA Score and Dietary Intake of EPA and DHA among 
U.S. Soldiers. Journal of the Academy of Nutrition and Dietetics 113: A26, 2013 
IRB study #1307011736 
 
Instructions: 
This questionnaire is about how much and how often you ate foods containing high levels of omega-3 fatty acids.  It is also about how much and 
how often you consume different beverages. When answering, think about what you usually ate and drank during the last six months. Please 
remember to include foods you ate in restaurants, as takeout food, and fish you or someone you know caught.  Complete PARTS 1-3. 
 
Part 1 Instructions: 
Step 1: Mark the column with an “X” to show how often on average you ate the food. 
Step 2: Mark your usual serving size with an “X”, as small (S), medium (M), or large (L). 
 
Please note: 
 
• A small serving is about one-half (1/2) the medium serving size, or less. 
• A large serving is about one-and-a half (1 ½) times the medium serving size or more. 
• If you never ate a food, mark “never” and omit the serving size. 
• Please do not skip any foods or leave blanks. 
• 4 ounces of cooked fish looks like the picture on the right : 
 
 
 
 
 
 
 
Example: This person never ate sushi, but ate a medium serving of baked or broiled white fish once a week. 
 
 NEVER or 
less than 
once per 
month 
1 per 
month 
2-3 
per 
month 
1 
per 
week 
2 
per 
week 
3-4 
per 
week 
5-6 
per 
week 
1 
per 
day 
2 + 
per day 
Medium 
Serving 
size 
S M L 
Sushi X         1 roll    
Baked or broiled white fish 
(such as snapper, cod, halibut, 
sole) 
   X      4 ounces  X  
Food Frequency Questionnaire from: Hanson JA, Lin Y, Strandjord SE, and Hibbeln JR. The Relationship between Omega-3 HUFA Score and Dietary Intake of EPA and DHA 
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PART 1 
How often did you eat these foods during the last 6 months? 
 NEVER or 
less than 
once per 
month 
1 per 
month 
2-3 
per 
month 
1 
per 
week 
2 
per 
week 
3-4 
per 
week 
5-6 
per 
week 
1 
per 
day 
2 + 
per day 
Medium 
Serving 
size 
S M L 
Canned tuna, tuna salad, tuna 
sandwich, tuna casserole 
         1 can or 
1 cup 
casserole 
   
Fried fish, fish sandwich, 
fish sticks 
         4 ounces 
or 1 
sand- 
witch 
   
Shellfish (shrimp, clams, 
oysters,  lobster, crayfish) 
         4 ounces    
Sardines          1 can    
Baked, broiled, or grilled white 
fish (such as snapper, cod, 
halibut, sole) 
         4 ounces    
Baked, broiled, or grilled dark 
or oily fish (such as salmon, 
mackerel, and bluefish) 
         4 ounces    
Sushi 
Please write type 
         2 rolls    
Beef          4 ounces    
Pork          4 ounces    
Dark chicken meat          2 pieces    
Eggs with yolks          2 egg    
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PART 2 
See the display for examples of foods enriched with DHA and/or other omega-3 fatty acids.  Did you eat any DHA or omega-3 enriched foods 
during the last 6 months? (Circle) YES or  NO 
If  NO skip to Part 3.  If YES, write in: 1) the food, 2) your usual serving size, and 3) how often eaten. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Food Usual Serving Size NEVER or 
less than 
once per 
month 
1 per 
month 
2-3 
per 
month 
1 
per 
week 
2 
per 
week 
3-4 
per 
week 
5-6 
per 
week 
1 
per day 
2 + 
per day 
Example : 
Horizon DHA milk 8 oz 
  
X 
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PART 3 
 
Did you take any nutritional supplements during the last 6 months? (Circle) Yes or No 
If NO, skip to end. If YES, how much and how often? 
 
Supplement How much did you normally take? 
Cod liver oil, fish oil, or omega -3 supplements  
 
 
1.   
Please Specify 
 
1.    
 2.   
2.   
Multivitamin  
 
 
1.   
Please Specify 
 
1.    
 2.   
2.   
Other vitamin, mineral or nutritional supplements  
 
 
1.   
Please Specify 
 
1.    
 2.   
2.   
END 
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